ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0894 • ACR Convergence 2022

    DAS28-gGT for the Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort

    Anne Dupont1, Arnaud Constantin2, Martin Soubrier3 and Jérôme Avouac4, 1Hôpital Cochin, AP-HP. Centre Université Paris-Cité, Paris, France, 2Toulouse University Hospital and University Toulouse III Paul Sabatier, Toulouse, France, 3Gabriel-Montpied Hospital, Clermont-Ferrand, France, 4University of Paris, Paris, France

    Background/Purpose: Patients with rheumatoid arthritis (RA) experience premature mortality that is largely due to cardiovascular disease (CVD). Ample evidence suggests that elevated γGT activity is…
  • Abstract Number: 0910 • ACR Convergence 2022

    Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies

    Albert Pérez-Isidro1, Raul Castellanos-Moreira1, Juan Camilo Sarmiento-Monroy2, Noemi de Moner1, Maresa Grundhuber3, Odette Vinas1, Raimon Sanmarti2 and Estibaliz Ruiz-Ortiz1, 1Hospital Clinic of Barcelona, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Thermo Fisher Scientific, Freiburg, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation. RA-associated interstitial lung disease (ILD) is the most frequent and severe extra-articular…
  • Abstract Number: 0926 • ACR Convergence 2022

    Methotrexate Polyglutamates Exposure – Response Modelling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate

    Renske Hebing1, Imke Bartelink2, Helen Gosselt3, Marry Lin3, Sandra Heil4, Robert De Jonge5 and Ron Mathot2, 1Amsterdam Rheumatology and immunology Center, Amsterdam UMC – location Reade, Amsterdam, Netherlands, 2Department of Pharmacy and Clinical Pharmacology, Amsterdam University Medical Centers – location AMC, Amsterdam, Netherlands, 3Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, 4Department of Clinical Chemistry, Erasmus MC, Rotterdam, Netherlands, 5Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, Netherlands

    Background/Purpose: Optimal dosing of low-dose methotrexate (MTX) is a challenge in rheumatoid arthritis (RA) because of substantial interpatient variation of response and because no stable…
  • Abstract Number: 1039 • ACR Convergence 2022

    Differential Retention of Adalimumab and Etanercept Biosimilars Compared to Originator Treatments: Results of a Retrospective French Multicentre Study

    Guillaume LARID1, Guy Baudens2, Alexis DANDURAND1, Pascal COQUERELLE3, Vincent Goeb4, Marie-Hélène Guyot5, Laurent Marguerie6, Frédéric MAURY7, Viellard Eric8, Eric Houvenagel9, Jean Hugues SALMON10, René-Marc Flipo11 and elisabeth gervais1, 1CHU Poitiers, Poitiers, France, 2Private practice, Valenciennes, France, 3CH Béthune, Béthune, France, 4CHU Amiens, Amiens, France, 5Private practice, Roubaix, France, 6Institut Calot, Berck-Sur-Mer, France, 7Private practice, Béthune, France, 8Private practice, St. Malo, France, 9Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, 10Reims University Hospital, Reims, France, 11CHU Lille, Boulogne-Billancourt, France

    Background/Purpose: Studies have demonstrated equivalence in term of efficacy and safety of biosimilars (bsDMARDs) compared to the originals treatments (boDMARDs) and in switching situation. Less…
  • Abstract Number: 1207 • ACR Convergence 2022

    Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid

    Huan Meng1, Steven H Lam2, Ho So1 and Lai-shan Tam3, 1The Faculty of Medicine, CUHK, Hong Kong, Hong Kong, 2The Chinese university of Hong Kong, Hong Kong, Hong Kong, 3The Chinese University of Hong Kong, Hong Kong, China

    Background/Purpose: Inflammatory arthritis (IA) including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to systematic inflammation. To elucidate whether inflammatory…
  • Abstract Number: 1331 • ACR Convergence 2022

    Risk Factors for Osteoporotic Fracture in Women with Established Long-Term Rheumatoid Arthritis

    Felipe Freire da Silva1, Gisela Machado2, ana Medeiros3, Karina Bonfiglioli4, Andrea Shimabuco2, Liliam Takayama5, Rosa Pereira6 and Diogo Domiciano7, 1FMUSP, Salvador, Brazil, 2FMUSP, São Paulo, Brazil, 3Faculdade de Medicina da Universidade de São Paulo, São Jose Dos Campos, Brazil, 4Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 5University of São Paulo, São Paulo, Brazil, 6Bone Metabolism Laboratory, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 7Hospital das Clinicas, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Low bone mineral density (BMD) is a predictor of osteoporotic fracture. However, individuals with Rheumatoid Arthritis (RA) who sustain "osteoporosis-related" fractures frequently have normal…
  • Abstract Number: 1394 • ACR Convergence 2022

    Identification of Joint Locations in an Early Rheumatoid Arthritis Cohort as a Characteristic of Disease Severity: DATA from the ERA-UCLouvain Brussels Cohort

    Laura Bricman1, Emilie Sapart2, Tatiana Sokolova3, Aleksandra avramovska2 and Patrick Durez4, 1Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, 2Rheumatology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 3Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, 4Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium

    Background/Purpose: Early RA patients (ERA pts) often present with different areas of joint involvement, but limited data exist to identify which specific joint locations may…
  • Abstract Number: 1410 • ACR Convergence 2022

    Subclinical Atherosclerosis Is Not Related with Acid Uric in Rheumatoid Arthritis: Study of 1005 Patients of a Single University Hospital

    Fabricio Benavides Villanueva1, Cristina Corrales1, Ivan Ferraz Amaro2, Nuria Vegas Revenga3, Ricardo Blanco4, Miguel Angel Gonzalez Gay5 and Alfonso Corrales6, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 3Hospital Galdakao- Usansolo, Galdakao, Spain, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 5Hospital Universitario Marques de Valdecilla, Lugo, Spain, 6Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain

    Background/Purpose: Rheumatoid Arthritis (RA) and Gout are related with increased cardiovascular (CV) disease. Carotid plaques and increased carotid intima-media thickness (cIMT) are surrogate markers of…
  • Abstract Number: 1429 • ACR Convergence 2022

    Acute Cardiovascular Events Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION Study

    jacques-eric gottenberg1, Nadir Mammar2, Meriem Kessouri2, Jeremie RUDANT2, nada Assi3, Benjamin grenier3 and julien kirchgesner4, 1Strasbourg University Hospital, Strasbourg, France, 2Pfizer, Paris, France, 3HEVA, Lyon, France, 4AP-HP, Paris, France

    Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis (RA), are at increased risk of major adverse cardiovascular event (MACE) compared with the general…
  • Abstract Number: 1604 • ACR Convergence 2022

    Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthritis in a Population with Baseline High Levels of Antibodies to Citrullinated Protein Antigens and Absence of Inflammatory Arthritis: Interim Analysis of the StopRA Trial

    Kevin D Deane1, Christopher Striebich2, Marie Feser3, Kristen Demoruelle3, LauraKay Moss4, Elizabeth Bemis3, Ashley Frazer-Abel4, Chelsie Fleischer4, Jeffrey Sparks5, Elizabeth Solow6, Judith James7, Joel Guthridge7, John Davis8, Jonathan Graf9, Jonathan Kay10, Maria Danila11, S. Louis Bridges, Jr.12, Lindsy Forbess13, James O'Dell14, Maureen McMahon15, Jennifer Grossman15, Diane Horowitz16, Athan Tiliakos17, Elena Schiopu18, David Fox19, Jeffrey Carlin20, Cristina Arriens7, Vivian Bykerk12, Reem Jan21, Mathilde Pioro22, M. Elaine Husni23, Ana Fernandez-Pokorny24, Sarah Walker25, Susan Booher26, Melissa Greenleaf27, Margie Byron25, Lynette Keyes-Elstein25, Ellen Goldmuntz28 and V. Michael Holers29, 1University of Colorado Denver Anschutz Medical Campus, Denver, CO, 2University of Colorado, Aurora, CO, 3University of Colorado Anschutz Medical Campus, Aurora, CO, 4University of Colorado Denver, Denver, CO, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 6UT Southwestern Medical Center, Dallas, TX, 7Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Mayo Clinic, Rochester, MN, 9Ucsf, San Francisco, CA, 10Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, 11University of Alabama at Birmingham, Birmingham, AL, 12Hospital for Special Surgery, New York, NY, 13Cedars-Sinai Medical Center, Los Angeles, CA, 14University of Nebraska Medical Center, Omaha, NE, 15University of California Los Angeles, Los Angeles, CA, 16Northwell Health, Jericho, NY, 17Emory University, Roswell, GA, 18Michigan Medicine, Ann Arbor, MI, 19University of Michigan, Ann Arbor, MI, 20Virginia Mason Medical Center, Seattle, WA, 21University of Chicago, Chicago, IL, 22University of Washington, Seattle, WA, 23Cleveland Clinic, Cleveland, OH, 24Essentia Health, Duluth, MN, 25Rho, Chapel Hill, NC, 26NIH NIAID, Bethesda, MD, 27NIH, Rock Hill, SC, 28NIAID/ NIH, Washington, DC, 29University of Colorado, Denver, CO

    Background/Purpose: The Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA) (ClinicalTrials.gov NCT02603146) is a randomized, double-masked, placebo-controlled, multi-center (20 sites) clinical trial evaluating…
  • Abstract Number: 1684 • ACR Convergence 2022

    A Potent Inhibitor of PAD4 Suppresses Histone Citrullination in Vitro and in Vivo

    Gundula Min-Oo, Victor Lira, Debbie Ruelas, Upasana Mehra, Graham Pimm, Taylor Won, Jean-Philippe Belzile, Kelly Wang, Claire Ellis, Blake Bleier, Paqui Gonzalez Traves, Nikolai Novikov, Adam Schrier and Anita Niedziela-Majka, Gilead Sciences, Foster City, CA

    Background/Purpose: Peptidyl arginine deaminase 4 (PAD4) catalyzes the conversion of arginine residues to citrulline, a post-translational modification that has been implicated in the auto-immune response…
  • Abstract Number: 1758 • ACR Convergence 2022

    Intake of Dairy Products as a Risk Factor for Rheumatoid Arthritis; A Nested Case-Control Study

    Camilla LIndegren1, Emily Sonestedt1, Emil Rydell1, Linnea Arvidsson1, Ulf Bergström1 and Carl Turesson2, 1Lund University, Malmö, Sweden, 2Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

    Background/Purpose: There has been increasing interest in diet as a factor that may contribute to the development of rheumatoid arthritis (RA). There is limited and…
  • Abstract Number: 1953 • ACR Convergence 2022

    Mortality in Rheumatoid Arthritis: Changing Causes and Predictive Factors. Study of a Cohort Followed Prospectively

    Cristina Corrales1, Fabricio Benavides Villanueva1, Ivan Ferraz Amaro2, Nuria Vegas Revenga3, Virgi Portilla4, Ricardo Blanco5, Miguel Ángel González-Gay6 and Alfonso Corrales4, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 3Hospital Galdakao- Usansolo, Galdakao, Spain, 4Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 6Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Patients with Rheumatoid Arthritis (RA) present an increased risk of mortality. In the last decades, mortality rates tended to decrease but cardiovascular (CV) events…
  • Abstract Number: 1970 • ACR Convergence 2022

    Detecting Inflammatory Changes in Seronegative Inflammatory Arthritis with Use of Musculoskeletal Ultrasound Studies

    Clarice P. Lin1 and Richard C. Chou2, 1University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Medicine, Buffalo, NY, 2University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Division of Allergy, Immunology, & Rheumatology, Department of Medicine, Buffalo, NY

    Background/Purpose: Recent clinical practice has increasingly utilized musculoskeletal (MS) ultrasound studies to assess inflammation and soft-tissue abnormalities of the joints, such as synovitis and bone…
  • Abstract Number: 1987 • ACR Convergence 2022

    Prednisone Use and the Incidence of Hyperglycemia or Diabetes in Patients with Rheumatoid Arthritis; A 10-year Sub Analysis of the BeSt Study

    CF Allaart1, Sytske Anne Bergstra2, Tom Huizinga1 and Joy van der Pol3, 1Leiden University Medical Center, Leiden, Netherlands, 2LUMC, Leiden, Netherlands, 3Leiden University Medical Center, Utrecht, Netherlands

    Background/Purpose: Use of prednisone in rheumatoid arthritis has been questioned because it may trigger side effects such as hyperglycemia and diabetes. However, disease activity (DAS)…
  • « Previous Page
  • 1
  • …
  • 94
  • 95
  • 96
  • 97
  • 98
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology